Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

A novel germline variant in the DOT1L gene co-segregating in a Dutch family with a history of melanoma.

Salgado C, Kwesi-Maliepaard EM, Jochemsen AG, Visser M, Harland M, van Leeuwen F, van Doorn R, Gruis N.

Melanoma Res. 2019 Dec;29(6):582-589. doi: 10.1097/CMR.0000000000000640.

PMID:
31524790
2.

HLA Expression in Uveal Melanoma: An Indicator of Malignancy and a Modifiable Immunological Target.

Souri Z, Wierenga APA, Mulder A, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 7;11(8). pii: E1132. doi: 10.3390/cancers11081132. Review.

3.

Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma.

Dogrusöz M, Ruschel Trasel A, Cao J, Ҫolak S, van Pelt SI, Kroes WGM, Teunisse AFAS, Alsafadi S, van Duinen SG, Luyten GPM, van der Velden PA, Amaro A, Pfeffer U, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1104. doi: 10.3390/cancers11081104.

4.

Loss of BAP1 Is Associated with Upregulation of the NFkB Pathway and Increased HLA Class I Expression in Uveal Melanoma.

Souri Z, Wierenga APA, van Weeghel C, van der Velden PA, Kroes WGM, Luyten GPM, van der Burg SH, Jochemsen AG, Jager MJ.

Cancers (Basel). 2019 Aug 2;11(8). pii: E1102. doi: 10.3390/cancers11081102.

5.

So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020.

Rodrigues M, Koning L, Coupland SE, Jochemsen AG, Marais R, Stern MH, Valente A, Barnhill R, Cassoux N, Evans A, Galloway I, Jager MJ, Kapiteijn E, Romanowska-Dixon B, Ryll B, Roman-Roman S, Piperno-Neumann S; UM Cure 2020 Consortium.

Cancers (Basel). 2019 Jul 22;11(7). pii: E1032. doi: 10.3390/cancers11071032.

6.

Correction for Danovi et al., "Amplification of Mdmx (or Mdm4) Directly Contributes to Tumor Formation by Inhibiting p53 Tumor Suppressor Activity".

Danovi D, Meulmeester E, Pasini D, Migliorini D, Capra M, Frenk R, de Graaf P, Francoz S, Gasparini P, Gobbi A, Helin K, Pelicci PG, Jochemsen AG, Marine JC.

Mol Cell Biol. 2019 Jul 16;39(15). pii: e00150-19. doi: 10.1128/MCB.00150-19. Print 2019 Aug 1. No abstract available.

7.

Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target.

Cao J, Pontes KC, Heijkants RC, Brouwer NJ, Groenewoud A, Jordanova ES, Marinkovic M, van Duinen S, Teunisse AF, Verdijk RM, Snaar-Jagalska E, Jochemsen AG, Jager MJ.

J Pathol. 2018 Aug;245(4):433-444. doi: 10.1002/path.5094. Epub 2018 Jun 23.

8.

Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.

Heijkants RC, Nieveen M, Hart KC', Teunisse AFAS, Jochemsen AG.

Oncogenesis. 2018 Mar 29;7(3):33. doi: 10.1038/s41389-018-0041-y.

9.

Functional analyses of a human vascular tumor FOS variant identify a novel degradation mechanism and a link to tumorigenesis.

van IJzendoorn DGP, Forghany Z, Liebelt F, Vertegaal AC, Jochemsen AG, Bovée JVMG, Szuhai K, Baker DA.

J Biol Chem. 2017 Dec 29;292(52):21282-21290. doi: 10.1074/jbc.C117.815845. Epub 2017 Nov 17.

10.

Fluorescent CXCR4 targeting peptide as alternative for antibody staining in Ewing sarcoma.

Sand LGL, Buckle T, van Leeuwen FWB, Corver WE, Kruisselbrink AB, Jochemsen AG, Hogendoorn PCW, Szuhai K.

BMC Cancer. 2017 May 26;17(1):383. doi: 10.1186/s12885-017-3352-z.

11.

Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy.

Cao J, Heijkants RC, Jochemsen AG, Dogrusöz M, de Lange MJ, van der Velden PA, van der Burg SH, Jager MJ, Verdijk RM.

Oncotarget. 2016 Jul 22;8(35):58021-58036. doi: 10.18632/oncotarget.10770. eCollection 2017 Aug 29.

12.

MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.

Marine JC, Jochemsen AG.

Cold Spring Harb Perspect Med. 2016 Jul 1;6(7). pii: a026237. doi: 10.1101/cshperspect.a026237. Review.

13.

Embryonic Zebrafish: Different Phenotypes after Injection of Human Uveal Melanoma Cells.

van der Ent W, Burrello C, de Lange MJ, van der Velden PA, Jochemsen AG, Jager MJ, Snaar-Jagalska BE.

Ocul Oncol Pathol. 2015 Apr;1(3):170-81. doi: 10.1159/000370159. Epub 2015 Apr 9. Review.

14.

Novel splice variants of CXCR4 identified by transcriptome sequencing.

Sand LG, Jochemsen AG, Beletkaia E, Schmidt T, Hogendoorn PC, Szuhai K.

Biochem Biophys Res Commun. 2015 Oct 9;466(1):89-94. doi: 10.1016/j.bbrc.2015.08.113. Epub 2015 Aug 28.

PMID:
26321665
15.

Interaction between p53 mutation and a somatic HDMX biomarker better defines metastatic potential in breast cancer.

Grawenda AM, Møller EK, Lam S, Repapi E, Teunisse AF, Alnæs GI, Børresen-Dale AL, Kristensen VN, Goding CR, Jochemsen AG, Edvardsen H, Bond GL.

Cancer Res. 2015 Feb 15;75(4):698-708. doi: 10.1158/0008-5472.CAN-14-2637. Epub 2015 Feb 3.

16.

Wild-type p53 inhibits pro-invasive properties of TGF-β3 in breast cancer, in part through regulation of EPHB2, a new TGF-β target gene.

Lam S, Wiercinska E, Teunisse AF, Lodder K, ten Dijke P, Jochemsen AG.

Breast Cancer Res Treat. 2014 Nov;148(1):7-18. doi: 10.1007/s10549-014-3147-8. Epub 2014 Sep 26.

PMID:
25257729
17.

Modeling of human uveal melanoma in zebrafish xenograft embryos.

van der Ent W, Burrello C, Teunisse AF, Ksander BR, van der Velden PA, Jager MJ, Jochemsen AG, Snaar-Jagalska BE.

Invest Ophthalmol Vis Sci. 2014 Sep 23;55(10):6612-22. doi: 10.1167/iovs.14-15202.

PMID:
25249605
18.

Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.

Bardot B, Bouarich-Bourimi R, Leemput J, Lejour V, Hamon A, Plancke L, Jochemsen AG, Simeonova I, Fang M, Toledo F.

Oncogene. 2015 May 28;34(22):2943-8. doi: 10.1038/onc.2014.230. Epub 2014 Aug 4.

PMID:
25088193
19.

Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.

van der Ent W, Jochemsen AG, Teunisse AF, Krens SF, Szuhai K, Spaink HP, Hogendoorn PC, Snaar-Jagalska BE.

J Pathol. 2014 Aug;233(4):415-24. doi: 10.1002/path.4378. Epub 2014 Jun 27.

PMID:
24974828
20.

The clinical development of p53-reactivating drugs in sarcomas - charting future therapeutic approaches and understanding the clinical molecular toxicology of Nutlins.

Biswas S, Killick E, Jochemsen AG, Lunec J.

Expert Opin Investig Drugs. 2014 May;23(5):629-45. doi: 10.1517/13543784.2014.892924. Epub 2014 Feb 28. Review.

PMID:
24579771
21.

Reactivation of p53 as therapeutic intervention for malignant melanoma.

Jochemsen AG.

Curr Opin Oncol. 2014 Jan;26(1):114-9. doi: 10.1097/CCO.0000000000000033. Review.

PMID:
24275854
22.

RNF4 is required for DNA double-strand break repair in vivo.

Vyas R, Kumar R, Clermont F, Helfricht A, Kalev P, Sotiropoulou P, Hendriks IA, Radaelli E, Hochepied T, Blanpain C, Sablina A, van Attikum H, Olsen JV, Jochemsen AG, Vertegaal AC, Marine JC.

Cell Death Differ. 2013 Mar;20(3):490-502. doi: 10.1038/cdd.2012.145. Epub 2012 Nov 30.

23.

High levels of Hdmx promote cell growth in a subset of uveal melanomas.

de Lange J, Teunisse AF, Vries MV, Lodder K, Lam S, Luyten GP, Bernal F, Jager MJ, Jochemsen AG.

Am J Cancer Res. 2012;2(5):492-507. Epub 2012 Aug 20.

24.

Microarray-based identification of age-dependent differences in gene expression of human dermal fibroblasts.

Dekker P, Gunn D, McBryan T, Dirks RW, van Heemst D, Lim FL, Jochemsen AG, Verlaan-de Vries M, Nagel J, Adams PD, Tanke HJ, Westendorp RG, Maier AB.

Mech Ageing Dev. 2012 Jul;133(7):498-507. doi: 10.1016/j.mad.2012.06.002. Epub 2012 Jun 18.

PMID:
22721680
25.

Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.

Lenos K, Grawenda AM, Lodder K, Kuijjer ML, Teunisse AF, Repapi E, Grochola LF, Bartel F, Hogendoorn PC, Wuerl P, Taubert H, Cleton-Jansen AM, Bond GL, Jochemsen AG.

Cancer Res. 2012 Aug 15;72(16):4074-84. Epub 2012 Jun 14.

26.

Mdmx: a p53 activator?

Jochemsen AG.

Cell Cycle. 2012 Mar 1;11(5):843. doi: 10.4161/cc.11.5.19597. Epub 2012 Mar 1. No abstract available.

PMID:
22356751
27.

Chk2 mediates RITA-induced apoptosis.

de Lange J, Verlaan-de Vries M, Teunisse AF, Jochemsen AG.

Cell Death Differ. 2012 Jun;19(6):980-9. doi: 10.1038/cdd.2011.182. Epub 2011 Dec 9.

28.

Oncogenic functions of hMDMX in in vitro transformation of primary human fibroblasts and embryonic retinoblasts.

Lenos K, de Lange J, Teunisse AF, Lodder K, Verlaan-de Vries M, Wiercinska E, van der Burg MJ, Szuhai K, Jochemsen AG.

Mol Cancer. 2011 Sep 12;10:111. doi: 10.1186/1476-4598-10-111.

29.

Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.

de Lange J, Ly LV, Lodder K, Verlaan-de Vries M, Teunisse AF, Jager MJ, Jochemsen AG.

Oncogene. 2012 Mar 1;31(9):1105-16. doi: 10.1038/onc.2011.309. Epub 2011 Jul 18.

PMID:
21765463
31.

Abrogation of Wip1 expression by RITA-activated p53 potentiates apoptosis induction via activation of ATM and inhibition of HdmX.

Spinnler C, Hedström E, Li H, de Lange J, Nikulenkov F, Teunisse AF, Verlaan-de Vries M, Grinkevich V, Jochemsen AG, Selivanova G.

Cell Death Differ. 2011 Nov;18(11):1736-45. doi: 10.1038/cdd.2011.45. Epub 2011 May 6.

32.

Functions of MDMX in the modulation of the p53-response.

Lenos K, Jochemsen AG.

J Biomed Biotechnol. 2011;2011:876173. doi: 10.1155/2011/876173. Epub 2011 Mar 22. Review.

33.

HDMX-L is expressed from a functional p53-responsive promoter in the first intron of the HDMX gene and participates in an autoregulatory feedback loop to control p53 activity.

Phillips A, Teunisse A, Lam S, Lodder K, Darley M, Emaduddin M, Wolf A, Richter J, de Lange J, Verlaan-de Vries M, Lenos K, Böhnke A, Bartel F, Blaydes JP, Jochemsen AG.

J Biol Chem. 2010 Sep 17;285(38):29111-27. doi: 10.1074/jbc.M110.129726. Epub 2010 Jul 20.

34.

USP10: friend and foe.

Jochemsen AG, Shiloh Y.

Cell. 2010 Feb 5;140(3):308-10. doi: 10.1016/j.cell.2010.01.034.

35.

Role of Mdm4 in drug sensitivity of breast cancer cells.

Lam S, Lodder K, Teunisse AF, Rabelink MJ, Schutte M, Jochemsen AG.

Oncogene. 2010 Apr 22;29(16):2415-26. doi: 10.1038/onc.2009.522. Epub 2010 Feb 8.

PMID:
20140020
36.

Identification and characterization of the first small molecule inhibitor of MDMX.

Reed D, Shen Y, Shelat AA, Arnold LA, Ferreira AM, Zhu F, Mills N, Smithson DC, Regni CA, Bashford D, Cicero SA, Schulman BA, Jochemsen AG, Guy RK, Dyer MA.

J Biol Chem. 2010 Apr 2;285(14):10786-96. doi: 10.1074/jbc.M109.056747. Epub 2010 Jan 15.

37.

Macrophage p53 controls macrophage death in atherosclerotic lesions of apolipoprotein E deficient mice.

Boesten LS, Zadelaar AS, van Nieuwkoop A, Hu L, Teunisse AF, Jochemsen AG, Evers B, van de Water B, Gijbels MJ, van Vlijmen BJ, Havekes LM, de Winther MP.

Atherosclerosis. 2009 Dec;207(2):399-404. doi: 10.1016/j.atherosclerosis.2009.06.015. Epub 2009 Jun 18.

PMID:
19608184
38.

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.

Hollestelle A, Nagel JH, Smid M, Lam S, Elstrodt F, Wasielewski M, Ng SS, French PJ, Peeters JK, Rozendaal MJ, Riaz M, Koopman DG, Ten Hagen TL, de Leeuw BH, Zwarthoff EC, Teunisse A, van der Spek PJ, Klijn JG, Dinjens WN, Ethier SP, Clevers H, Jochemsen AG, den Bakker MA, Foekens JA, Martens JW, Schutte M.

Breast Cancer Res Treat. 2010 May;121(1):53-64. doi: 10.1007/s10549-009-0460-8. Epub 2009 Jul 11.

PMID:
19593635
39.

Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases.

Wang YV, Leblanc M, Wade M, Jochemsen AG, Wahl GM.

Cancer Cell. 2009 Jul 7;16(1):33-43. doi: 10.1016/j.ccr.2009.05.008.

40.

Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2.

Ohtsubo C, Shiokawa D, Kodama M, Gaiddon C, Nakagama H, Jochemsen AG, Taya Y, Okamoto K.

Cancer Sci. 2009 Jul;100(7):1291-9. doi: 10.1111/j.1349-7006.2009.01180.x. Epub 2009 Apr 27.

41.

c-Abl phosphorylates Hdmx and regulates its interaction with p53.

Zuckerman V, Lenos K, Popowicz GM, Silberman I, Grossman T, Marine JC, Holak TA, Jochemsen AG, Haupt Y.

J Biol Chem. 2009 Feb 6;284(6):4031-9. doi: 10.1074/jbc.M809211200. Epub 2008 Dec 15.

42.

Mdm2 induces mono-ubiquitination of FOXO4.

Brenkman AB, de Keizer PL, van den Broek NJ, Jochemsen AG, Burgering BM.

PLoS One. 2008 Jul 30;3(7):e2819. doi: 10.1371/journal.pone.0002819.

43.

Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro.

Schrage YM, Lam S, Jochemsen AG, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC, Bovée JV.

J Cell Mol Med. 2009 Sep;13(9A):2843-52. doi: 10.1111/j.1582-4934.2008.00406.x. Epub 2008 Jun 27.

44.

p53: a guide to apoptosis.

Meulmeester E, Jochemsen AG.

Curr Cancer Drug Targets. 2008 Mar;8(2):87-97. Review.

PMID:
18336191
45.

Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis.

Benosman S, Gross I, Clarke N, Jochemsen AG, Okamoto K, Loeffler JP, Gaiddon C.

Cell Death Differ. 2007 Dec;14(12):2047-57. Epub 2007 Sep 7.

46.

MDMX: from bench to bedside.

Marine JC, Dyer MA, Jochemsen AG.

J Cell Sci. 2007 Feb 1;120(Pt 3):371-8. Review.

47.

Inactivation of the p53 pathway in retinoblastoma.

Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG, Dyer MA.

Nature. 2006 Nov 2;444(7115):61-6.

PMID:
17080083
48.

Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage.

Pereg Y, Lam S, Teunisse A, Biton S, Meulmeester E, Mittelman L, Buscemi G, Okamoto K, Taya Y, Shiloh Y, Jochemsen AG.

Mol Cell Biol. 2006 Sep;26(18):6819-31.

49.

Mdm2, but not Mdm4, protects terminally differentiated smooth muscle cells from p53-mediated caspase-3-independent cell death.

Boesten LS, Zadelaar SM, De Clercq S, Francoz S, van Nieuwkoop A, Biessen EA, Hofmann F, Feil S, Feil R, Jochemsen AG, Zurcher C, Havekes LM, van Vlijmen BJ, Marine JC.

Cell Death Differ. 2006 Dec;13(12):2089-98. Epub 2006 May 26.

50.

DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation.

Okamoto K, Kashima K, Pereg Y, Ishida M, Yamazaki S, Nota A, Teunisse A, Migliorini D, Kitabayashi I, Marine JC, Prives C, Shiloh Y, Jochemsen AG, Taya Y.

Mol Cell Biol. 2005 Nov;25(21):9608-20.

Supplemental Content

Loading ...
Support Center